HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetics News In Brief: CIR Panel To Review Preservative; ICCR Prep; More

This article was originally published in The Rose Sheet

Executive Summary

With use of preservative polyaminopropyl biguanide potentially on the rise, the CIR Expert Panel will evaluate the ingredient for safety at its upcoming meeting in Washington. More cosmetics news in brief, including developments at Unilever and Coty.

You may also be interested in...



Unilever Goes Local With Personal-Care Innovation, Projects H2 Impacts

The Anglo-Dutch firm has been slashing costs and establishing teams in local markets to lay the groundwork for R&D and marketing investments that are expected to pay off in the fiscal 2017 second half. During a July 20 call with investors, CEO Paul Polman discussed local innovations that are already making waves.

ICCR Aims To Establish Standards For Cosmetics Risk Assessment

The International Cooperation on Cosmetics Regulation is working to develop consensus regarding risk-assessment, which the Personal Care Products Council expects will be a valuable resource for companies and other authorities around the world. Meanwhile, preservative initiatives remain a priority for the regulator group.

Unilever Reviewing Its Biz After Rejecting Kraft Heinz Takeover Bid

Unilever reportedly is exploring options including acquisitions or a spin-off of its food business following Kraft Heinz’s withdrawal of a $143bn takeover bid. The firm may be under pressure to deliver accelerated shareholder value after rebuffing the offer, which it said undervalued the company and was not strategically attractive.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel